Managing alcohol use and multiple medications for people aging with HIV
The HIV and Alcohol Research center focused on Polypharmacy (HARP)
This center develops personalized ways to reduce harm from drinking and from taking many medicines in people aging with HIV.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11172516 on NIH RePORTER |
What this research studies
Researchers will analyze large national Veterans Health Administration medical records and blood alcohol biomarkers to learn how unhealthy drinking and taking five or more medications together affect health in people aging with HIV. They will combine genetic risk information with real-world data to help pick safer medication choices and identify drugs that could be repurposed to treat alcohol problems. The team will use high-performance computing and advanced analytics to summarize multiple risk factors and find actionable signals. Core labs and VA clinics may also enable collection of biomarkers and patient-level data where needed.
Who could benefit from this research
Good fit: People aging with HIV who drink alcohol (at-risk drinkers or those with Alcohol Use Disorder) and who are taking five or more medications, particularly patients receiving care in the U.S. VA system.
Not a fit: People without HIV, people who do not drink alcohol, or those taking few medications are unlikely to be helped directly by this research.
Why it matters
Potential benefit: If successful, this work could lead to personalized plans that lower liver damage, reduce harmful drug interactions, and improve treatment options for alcohol problems in people aging with HIV.
How similar studies have performed: Large database studies have shown links between alcohol, polypharmacy, and harm and biomarkers like PEth and genetic approaches show promise, but combining these methods to guide personalized medication choices is relatively new.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Justice, Amy Caroline — Yale University
- Study coordinator: Justice, Amy Caroline
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.